The APOE genotype, imaging markers of SVD (such as, CMBs, white matter hyperintensities, and lacunar infarcts), and CSF biomarkers in dementia have previously been investigated and have shown lower CSF Aβ42 levels with the presence of CMBs and white matter hyperintensities in APOE ε4 carriers, reflecting increased deposition of Aβ42 in the brain parenchyma (Shoamanesh et al., 2014). This evidence concerns the gene APOE and dementia.